Raymond Cross, MD
Gastroenterology · Baltimore, MDNPI 1447214507
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $215,844 of the $340,949 with a category attached, or 63.3%. 36 manufacturers reported payments, led by AbbVie at 30.5% of the total. 2025 is the largest year on record at $101,768, 2.9 times the $34,623 reported in 2019. Among gastroenterology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 533 payments — averaging $639.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$104K
- Johnson & Johnson$103K
- Pfizer$47K
- Janssen Scientific Affairs, LLC$24K
- E.r. Squibb & Sons, L.L.C.$20K
- Takeda Pharmaceuticals U.S.A., Inc.$14K
- plus $29K from 30 others
Across 140 payments — averaging $6219.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$321K
- Janssen Research & Development, LLC$235K
- Gilead$192K
- AbbVie$50K
- Eli Lilly$36K
- F. Hoffmann-la Roche AG$11K
- plus $25K from 3 others
What the payments were for
- Consulting fees$215,84463%
- Speaking & faculty fees$94,34528%
- Travel & lodging$18,5825%
- Food & beverage$12,1794%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 134 | $103,890 |
| Johnson & Johnson | 129 | $102,539 |
| Pfizer | 66 | $47,268 |
| Janssen Scientific Affairs, LLC | 51 | $24,426 |
| E.r. Squibb & Sons, L.L.C. | 18 | $20,163 |
| Takeda Pharmaceuticals U.S.A., Inc. | 58 | $13,775 |
| Hexal AG | 2 | $9,360 |
| Bristol Myers Squibb | 26 | $4,303 |
| Pharmacosmos Therapeutics Inc. | 1 | $3,340 |
| Eli Lilly | 1 | $2,700 |
| Gilead | 4 | $2,419 |
| Samsung Bioepis Co., Ltd. | 3 | $2,300 |
| Janssen Global Services, LLC | 1 | $1,515 |
| Genentech, Inc. | 1 | $850 |
| Fresenius Kabi USA, LLC | 1 | $610 |
| Sebela Pharmaceuticals Inc. | 1 | $500 |
| Medtronic | 1 | $146 |
| Mallinckrodt Hospital Products Inc. | 4 | $111 |
| Digestive Care, Inc. | 3 | $103 |
| Lilly USA, LLC | 4 | $94 |
| Boston Scientific | 1 | $71 |
| Madrigal Pharmaceuticals | 2 | $53 |
| Amgen | 2 | $52 |
| Shionogi Inc | 3 | $51 |
| UCB, Inc. | 2 | $41 |
| Celltrion USA Inc. | 2 | $41 |
| Phathom Pharmaceuticals, Inc. | 2 | $36 |
| Alnylam Pharmaceuticals Inc. | 2 | $33 |
| Sanofi | 1 | $30 |
| Eisai Inc. | 1 | $27 |
| AstraZeneca | 1 | $23 |
| Intercept Pharmaceuticals, Inc. | 1 | $19 |
| Sandoz | 1 | $17 |
| Mirum Pharmaceuticals, Inc. | 1 | $17 |
| Dynavax Technologies Corporation | 1 | $15 |
| Ferring Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$340,949 in reported general payments places this provider in the 95th percentile of 455 gastroenterology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 37 | $1,333,023 |
| GattexTeduglutide | 15 | $695,467 |
| Humira(Cf) PenAdalimumab | 54 | $567,397 |
| Skyrizi On-BodyRisankizumab-Rzaa | 16 | $317,486 |
| RinvoqUpadacitinib | 18 | $168,560 |
| Entyvio PenVedolizumab | 12 | $134,215 |
| XifaxanRifaximin | 11 | $31,500 |
| Mesalamine | 31 | $12,037 |
| Budesonide EcBudesonide | 11 | $3,325 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 28 | $1,515 |
| Budesonide DrBudesonide | 12 | $1,489 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 17 | $1,242 |
| Omeprazole | 49 | $1,201 |
| Sulfasalazine | 12 | $1,142 |
| Azathioprine | 11 | $719 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $102,539 | $1,333,02337 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gattex | $13,775 | $695,46715 claims |
| AbbVieRinvoq | $103,890 | $168,56018 claims |
| SandozLansoprazole | $17 | $29713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 455 gastroenterology providers in Maryland.
Other gastroenterology in Baltimore
- Sergey KantsevoyBaltimore$1.1M
- Anurag MaheshwariBaltimore$803K
- Aline Charabaty PishvaianBaltimore$631K
- Mouen KhashabBaltimore$440K
- Paul ThuluvathBaltimore$231K
- Niraj JaniBaltimore$214K
- Aminur KhanBaltimore$118K
- Eric GoldbergBaltimore$110K
- Saowanee NgamruengphongBaltimore$90K
- Venkata AkshintalaBaltimore$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.